Pipeline

Key proprietary programs

• SYX-5219 – for the treatment of atopic dermatitis

  SYX-5219 offers first-in-class potential as an oral, disease-modifying anti-inflammatory therapy, targeting a critical enzyme that regulates cell metabolism called pyruvate kinase M2 (PKM2). Modulation of PKM2 alters B and T lymphocyte function with the potential to normalise immune cell function and drive sustained disease remission in atopic dermatitis (eczema).

• SIT-047 – for the treatment of psoriatic arthritis

  SIT-47 is an oral, selective MTHFD2 inhibitor and offers first-in-class potential as a disease-modifying treatment for psoriatic arthritis. By targeting MTHFD2, a key enzyme in one-carbon metabolism, SIT-047 is designed to regulate the activity of Th1 and Th17, immune cell subsets known to drive disease pathology in psoriatic arthritis. 

• SIT-052 – for the treatment of moderate to severe allergic asthma

  SIT-052 is a GLS1 inhibitor which attenuates auto-immune responses associated with atopic diseases including allergic asthma. Sitryx’s novel oral GLS1 inhibitors demonstrate significant disease control in diverse preclinical inflammatory and autoimmune models. SIT-052 has the potential to be a first in class treatment for people with moderate to severe asthma offering biologic-like disease control from an oral small molecule.

• SIT-033 – for the treatment of ulcerative colitis

  SIT-033 is a SIK2 Inhibitor, which unlike early SIK inhibitors, is able to selectively target isozymes to maximise efficacy and therapeutic index in ulcerative colitis. Sitryx’s isozyme selective SIK2 inhibition offers the potential for sustained disease remission and improved safety profile in moderate to severe ulcerative colitis.